Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
T
TAP Pharmaceutical Products, Inc.
Pharmaceutical Preparation ManufacturingUnited States
Last verified 2 years ago
TAP Pharmaceutical Products, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 1970, the company has established itself as a leader in the development and marketing of innovative therapies, particularly in the fields of urology and oncology. TAP is renowned for its flagship product, Lupron, which has transformed the treatment landscape for prostate cancer and other hormone-related conditions.
With a strong presence across North America and significant operations in various global markets, TAP Pharmaceutical Products has achieved notable milestones, including strategic partnerships that enhance its research capabilities. The company is committed to advancing patient care through its unique offerings, which combine cutting-edge science with a patient-centric approach. TAP's dedication to quality and innovation solidifies its position as a trusted name in the pharmaceutical sector.
100
DitchCarbon score
+58 vs industry average
TAP Pharmaceutical Products, Inc.’s score of 100 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at TAP Pharmaceutical Products, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for TAP Pharmaceutical Products, Inc. yet.
TAP Pharmaceutical Products, Inc.'s reported carbon emissions
TAP Pharmaceutical Products, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is part of a corporate family that includes Takeda Pharmaceutical Company Limited, from which it inherits emissions data and climate commitments.
As a merged entity, TAP Pharmaceutical Products aligns its climate initiatives with those of Takeda. Takeda has set ambitious targets for carbon reduction, which are cascaded down to TAP. These initiatives include commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which aim to enhance transparency and accountability in emissions reporting.
While specific reduction targets for TAP Pharmaceutical Products are not detailed, the overarching goals from Takeda include significant reductions in Scope 1, 2, and 3 emissions. The company is actively working towards sustainability and reducing its carbon footprint, reflecting a commitment to addressing climate change within the pharmaceutical industry.
In summary, TAP Pharmaceutical Products, Inc. is committed to climate action through its association with Takeda Pharmaceutical Company Limited, although specific emissions data and reduction targets for TAP are currently unavailable.
Assessing TAP Pharmaceutical Products, Inc. as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for TAP Pharmaceutical Products, Inc. and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
TAP Pharmaceutical Products, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for TAP Pharmaceutical Products, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Takeda Pharmaceutical Company LimitedFY2030 targetSee details
Active
Carbon Disclosure Project
Inherited from Takeda Pharmaceutical Company LimitedSign in to view
Active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
Inherited from Takeda Pharmaceutical Company LimitedSee details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for TAP Pharmaceutical Products, Inc. yet.
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more